Vascular smooth muscle cells contribute to APOL1-induced podocyte injury in HIV milieu

Experimental and Molecular Pathology

Volumn 98, Issue 3, 2015, Pages 491-501

  Lan, Xiqian ^a   Wen, Hongxiu ^a   Saleem, Moin A ^b   Mikulak, Joanna ^c   Malhotra, Ashwani ^a   Skorecki, Karl ^d   Singhal, Pravin C ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; PROTEIN APOL1; RECOMBINANT GAMMA INTERFERON; SECRETORY PROTEIN; UNCLASSIFIED DRUG; APOL1 PROTEIN, HUMAN; APOLIPOPROTEIN; CULTURE MEDIUM; HIGH DENSITY LIPOPROTEIN;

APOL1 GENE; ARTICLE; CELL DAMAGE; CELL LOSS; CELL MEDIATED CYTOTOXICITY; CELL SWELLING; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE; GENE OVEREXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYSOSOME; PERIPHERAL BLOOD MONONUCLEAR CELL; PODOCYTE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN SECRETION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; CELL LINE; CULTURE MEDIUM; DRUG EFFECTS; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; METABOLISM; MONOCYTE; PATHOGENICITY; PHARMACOLOGY; VIROLOGY;

APOLIPOPROTEINS; CELL LINE; CULTURE MEDIA, CONDITIONED; HIV; HUMANS; LIPOPROTEINS, HDL; MONOCYTES; MUSCLE, SMOOTH, VASCULAR; PODOCYTES;

EID: 84926302543     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2015.03.020     Document Type: Article

References (43)

1. Bechtel W., Helmstädter M., Balica J., Hartleben B., Kiefer B., Hrnjic F., Schell C., Kretz O., Liu S., Geist F., Kerjaschki D., Walz G., Huber T.B. Vps34 deficiency reveals the importance of endocytosis for podocyte homeostasis. J. Am. Soc. Nephrol. 2013, 24:727-743.
2. Benlahrech A., Patterson S. HIV-1 infection and induction of interferon alpha in plasmacytoid dendritic cells. Curr. Opin. HIV AIDS 2011, 6:373-378.
3. Bruggeman L.A., O'Toole J.F., Ross M.D., Madhavan S.M., Smurzynski M., Wu K., Bosch R.J., Gupta S., Pollak M.R., Sedor J.R., Kalayjian R.C. Plasma apolipoprotein L1 levels do not correlate with CKD. J. Am. Soc. Nephrol. 2014, 25:634-644.
4. Castro J., Bittner C.X., Humeres A., Montecinos V.P., Vera J.C., Barros L.F. A cytosolic source of calcium unveiled by hydrogen peroxide with relevance for epithelial cell death. Cell Death Differ. 2004, 11:468-478.
5. Chandel N., Sharma B., Husain M., Salhan D., Singh T., Rai P., Mathieson P.W., Saleem M.A., Malhotra A., Singhal P.C. HIV compromises integrity of the podocyte actin cytoskeleton through downregulation of the vitamin D receptor. Am. J. Physiol. Ren. Physiol. 2013, 304:F1347-F1357.
6. Cui H.L., Ditiatkovski M., Kesani R., Bobryshev Y.V., Liu Y., Geyer M., Mukhamedova N., Bukrinsky M., Sviridov D. HIV protein Nef causes dyslipidemia and formation of foam cells in mouse models of atherosclerosis. FASEB J. 2014, 287:2828-2839.
7. Diamond J.R., Karnovsky M.J. Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int. 1988, 33:917-924.
8. Duchateau P.N., Pullinger C.R., Orellana R.E., Kunitake S.T., Naya-Vigne J., O'Connor P.M., Malloy M.J., Kane J.P. Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. J. Biol. Chem. 1997, 272:25576-25582.
9. Duro M., Sarmento-Castro R., Almeida C., Medeiros R., Rebelo I. Lipid profile changes by high activity anti-retroviral therapy. Clin. Biochem. 2013, 46:740-744.
10. Eugenin E.A., Morgello S., Klotman M.E., Mosoian A., Lento P.A., Berman J.W., Schecter A.D. Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease. Am. J. Pathol. 2008, 172:1100-1111.
11. Falusi O.M., Aberg J.A. HIV and cardiovascular risk factors. AIDS Read. 2001, 11:263-268.
12. Foster M.C., Coresh J., Fornage M., Astor B.C., Grams M., Franceschini N., Kao W.L. APOL1 variants associate with increased risk of CKD among African Americans. J. Am. Soc. Nephrol. 2013, 24:1484-1491.
13. Freedman B.I., Langefeld C.D., Lu L., Palmer N.D., Carrie Smith S., Bagwell B.M., Hicks P.J., Xu J., Wagenknecht L.E., Raffield L.M., Register T.C., Jeffrey Carr J., Bowden D.W., Divers J. APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes. Kidney Int. 2015, 87:176-181.
14. Friedman D.J., Kozlitina J., Genovese G., Jog P., Pollak M.R. Population-based risk assessment of APOL1 on renal disease. J. Am. Soc. Nephrol. 2011, 22:2098-2105.
15. Genovese G., Friedman D.J., Ross M.D., Lecordier L., Uzureau P., Freedman B.I., Bowden D.W., Langefeld C.D., Oleksyk T.K., Uscinski Knob A.L., Bernhardy A.J., Hicks P.J., Nelson G.W., Vanhollebeke B., Winkler C.A., Kopp J.B., Pays E., Pollak M.R. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010, 329:841-845.
16. Genovese G., Friedman D.J., Pollak M.R. APOL1 variants and kidney disease in people of recent African ancestry. Nat. Rev. Nephrol. 2013, 9:240-244.
17. Gerthoffer W.T., Singer C.A. Secretory functions of smooth muscle: cytokines and growth factors. Mol. Interv. 2002, 2:447-456.
18. Gonzalez-Villalobos R.A., Janjoulia T., Fletcher N.K., Giani J.F., Nguyen M.T., Riquier-Brison A.D., Seth D.M., Fuchs S., Eladari D., Picard N., Bachmann S., Delpire E., Peti-Peterdi J., Navar L.G., Bernstein K.E., McDonough A.A. The absence of intrarenal ACE protects against hypertension. J. Clin. Invest. 2013, 123:2011-2023.
19. Husain M., Meggs L.G., Vashistha H., Simoes S., Griffiths K.O., Kumar D., Mikulak J., Mathieson P.W., Saleem M.A., Del Valle L., Pina-Oviedo S., Wang J.Y., Seshan S.V., Malhotra A., Reiss K., Singhal P.C. Inhibition of p66ShcA longevity gene rescues podocytes from HIV-1-induced oxidative stress and apoptosis. J. Biol. Chem. 2009, 284:16648-16658.
20. Ito K., Bick A.G., Flannick J., Friedman D.J., Genovese G., Parfenov M.G., Depalma S.R., Gupta N., Gabriel S.B., Taylor H.A., Fox E.R., Newton-Cheh C., Kathiresan S., Hirschhorn J.N., Altshuler D.M., Pollak M.R., Wilson J.G., Seidman J.G., Seidman C. Increased burden of cardiovascular disease in carriers of APOL1 genetic variants. Circ. Res. 2014, 114:845-850.
21. Johnstone D.B., Shegokar V., Nihalani D., Rathore Y.S., Mallik L., Ashish Zare V., Ikizler H.O., Powar R., Holzman L.B. APOL1 null alleles from a rural village in India do not correlate with glomerulosclerosis. PLoS One 2012, 7:e51546.
22. Kopp J.B. Rethinking hypertensive kidney disease: arterionephrosclerosis as a genetic, metabolic, and inflammatory disorder. Curr. Opin. Nephrol. Hypertens. 2013, 22:266-267.
23. Kopp J.B., Nelson G.W., Sampath K., Johnson R.C., Genovese G., An P., Friedman D., Briggs W., Dart R., Korbet S., Mokrzycki M.H., Kimmel P.L., Limou S., Ahuja T.S., Berns J.S., Fryc J., Simon E.E., Smith M.C., Trachtman H., Michel D.M., Schelling J.R., Vlahov D., Pollak M., Winkler C.A. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J. Am. Soc. Nephrol. 2011, 22:2129-2137.
24. Lan X., Jhaveri A., Cheng K., Wen H., Saleem M.A., Mathieson P.W., Mikulak J., Aviram S., Malhotra A., Skorecki K., Singhal P.C. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability. Am. J. Physiol. Ren. Physiol. 2014, 307:F326-F336.
25. Langefeld C.D., Divers J., Pajewski N.M., Hawfield A.T., Reboussin D.M., Bild D.E., Kaysen G.A., Kimmel P.L., Raj D.S., Ricardo A.C., Wright J.T., Sedor J.R., Rocco M.V., Freedman B.I. Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the systolic blood pressure intervention trial. Kidney Int. 2015, 87(1):169-175.
26. Ma L., Shelness G.S., Snipes J.A., Murea M., Antinozzi P.A., Cheng D., Saleem M.A., Satchell S.C., Banas B., Mathieson P.W., Kretzler M., Hemal A.K., Rudel L.L., Petrovic S., Weckerle A., Pollak M.R., Ross M.D., Parks J.S., Freedman B.I. Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines. J. Am. Soc. Nephrol. 2015, 26:339-348.
27. Madhavan S.M., O'Toole J.F., Konieczkowski M., Ganesan S., Bruggeman L.A., Sedor J.R. APOL1 localization in normal kidney and nondiabetic kidney disease. J. Am. Soc. Nephrol. 2011, 22:2119-2128.
28. Medapalli R.K., He J.C., Klotman P.E. HIV-associated nephropathy: pathogenesis. Curr. Opin. Nephrol. Hypertens. 2011, 20:306-311.
29. Mikulak J., Teichberg S., Arora S., Kumar D., Yadav A., Salhan D., Pullagura S., Mathieson P.M., Saleem M.A., Singhal P.C. DC-specific ICAM-3-grabbing nonintegrin mediates internalization of HIV-1 into human podocytes. Am. J. Physiol. Ren. Physiol. 2010, 299(3):F664-F673.
30. Mujawar Z., Tamehiro N., Grant A., Sviridov D., Bukrinsky M., Fitzgerald M.L. Mutation of the ATP cassette binding transporter A1 (ABCA1) C-terminus disrupts HIV-1 Nef binding but does not block the Nef enhancement of ABCA1 protein degradation. Biochemistry 2010, 49:8338-8349.
31. Mundel P., Shankland S.J. Podocyte biology and response to injury. J. Am. Soc. Nephrol. 2002, 13:3005-3015.
32. Nichols B., Jog P., Lee J.H., Blackler D., Wilmot M., D'Agati V., Markowitz G., Kopp J.B., Alper S.L., Pollak M.R., Friedman D.J. Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. Kidney Int. 2014, (Aug 6, [Epub ahead of print]). 10.1038/ki.2014.270.
33. Page N.M., Butlin D.J., Lomthaisong K., Lowry P.J. The human apolipoprotein L gene cluster: identification, classification, and sites of distribution. Genomics 2001, 74:71-78.
34. Quaggin S.E., George A.L. Apolipoprotein l1 and the genetic basis for racial disparity in chronic kidney disease. J. Am. Soc. Nephrol. 2011, 22:1955-1958.
35. Saleem M.A., O'Hare M.J., Reiser J., Coward R.J., Inward C.D., Farren T., Xing C.Y., Ni L., Mathieson P.W., Mundel P. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J. Am. Soc. Nephrol. 2002, 13:630-638.
36. Segal J.L., Thompson J.F., Charter R.A. A novel immunogen to modulate cytokine production and promote immune system reconstitution in HIV-AIDS. Am. J. Ther. 2012, 19:317-323.
37. Skorecki K.L., Wasser W.G. Hypertension-misattributed kidney disease in African Americans. Kidney Int. 2013, 83:6-9.
38. Thomson R., Genovese G., Canon C., Kovacsics D., Higgins M.K., Carrington M., Winkler C.A., Kopp J., Rotimi C., Adeyemo A., Doumatey A., Ayodo G., Alper S.L., Pollak M.R., Friedman D.J., Raper J. Evolution of the primate trypanolytic factor APOL1. PNAS 2014, 111:E2130-E2139.
39. Tzur S., Rosset S., Shemer R., Yudkovsky G., Selig S., Tarekegn A., Bekele E., Bradman N., Wasser W.G., Behar D.M., Skorecki K. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum. Genet. 2010, 128:345-350.
40. Wan G., Zhaorigetu S., Liu Z., Kaini R., Jiang Z., Hu C.A. Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. J. Biol. Chem. 2008, 283:21540-21549.
41. Weide T., Huber T. Implications of autophagy for glomerular aging and disease. Cell Tissue Res. 2011, 343:467-473.
42. Wiggins R.C., Alpers C.E., Holzman L.B., He J.C., Salant D.J., Chugh S.S., Natarajan R., Trachtman H., Brasile L., Star R.A., Rys-Sikora K.E., Moxey-Mims M.M., Flessner M.F. Kidney research national dialogue. Glomerular disease: looking beyond pathology. Clin. J. Am. Soc. Nephrol. 2014, 9:1138-1140.
43. Zhaorigetu S., Wan G., Kaini R., Jiang Z., Chien-an A.H. ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death. Autophagy 2008, 4:1079-1082.